Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 107

Results For "RIL"

1067 News Found

Pharma sector will be $130 billion strong by 2030: EY-FICCI paper
News | March 04, 2021

Pharma sector will be $130 billion strong by 2030: EY-FICCI paper

The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades


2021 will be a game-changer for pharma industry, says experts
News | February 13, 2021

2021 will be a game-changer for pharma industry, says experts

The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse


Approval accorded under PLI Scheme for domestic manufacturing of medical devices
News | February 12, 2021

Approval accorded under PLI Scheme for domestic manufacturing of medical devices

The medical device Sector in India suffers from a considerable cost of manufacturing disability.


ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12
News | February 11, 2021

ICN to organise E-conference on India's Pharma Industry Outlook on Feb 12

Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.


Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21
News | February 01, 2021

Dr. Reddy's Laboratories reports Rs. 19.8 Cr PAT in Q3FY21

The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.


Lonza reports 12% sales growth in 2020
News | January 28, 2021

Lonza reports 12% sales growth in 2020

Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.


Dr. Reddy’s seeks approval to continue Phase 3 trial
News | January 13, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial

The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.